Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Legal status === In 2017, inotuzumab ozogamicin was approved by the European Commission and the US Food and Drug Administration for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia under the brand name Besponsa (Pfizer/Wyeth).
5-HTP robustly produces the head-twitch response (HTR) in rodents when administered at relatively high doses. It dose-dependently induces the HTR in mice across a dose range of 50 to 250 mg/kg via intraperitoneal administration, with an inverted U-shaped dose–response curve and maximal induction of the HTR at a dose of 200 mg/kg. Similarly to the case of 5-HTP, intracerebroventricular injection of serotonin, but not peripheral administration of serotonin, produces the HTR. The HTR is induced by serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin and is a behavioral proxy of psychedelic effects. The HTR of 5-HTP is blocked by serotonin 5-HT2A receptor antagonists, which block the hallucinogenic effects of serotonergic psychedelics in humans, is prevented by aromatic L-amino acid decarboxylase (AAAD) inhibitors, which block conversion of 5-HTP into serotonin, and is potentiated by monoamine oxidase A (MAO-A) inhibitors, which prevent the degradation of serotonin and other endogenous tryptamines. It is also suppressed by the serotonin 5-HT1A receptor full agonist 8-OH-DPAT, is greatly augmented by the serotonin 5-HT2C receptor antagonist RS-102221, and is reduced by the trace amine-associated receptor 1 (TAAR1) antagonist EPPTB.
=== Military operations === With its built-in stairs and below deck holds, the Il-86 was widely expected to serve in the personnel transport role with the Soviet air forces: "The wide-bodied Il-86 can perform not only as a troop transport ... but may also in the future form the basis for a command and control aircraft for airborne coordination of Warsaw Pact forces." In the event, four airframes (c/n 042, 043, 046 and 048, carrying quasi-civil registrations SSSR-86146, '7, '8 and '9) were delivered to the 8th Special Purposes Aviation Division at the Chkalovsky air base near Moscow. These are variously claimed to be designated Il-80, Il-82, Il-87 or Il-86VKP (Russian: “ВКП” for “воздушный командный пост”; transliterated: "vozdushniy komandnyi post" “veh-kah-peh” and meaning "aerial command post"). This version has the NATO reporting name Maxdome.
Knockout mutants for FUT4 and FUT6 showed severe inhibition in root growth under salt conditions while knockout mutants for GlcAT14A, GlcAT14B, and GlcAT14C showed enhanced cell elongation rates in dark grown hypocotyls and light grown roots during seedling growth. In the case of ray1 mutant seedlings grown on vertical plates, the length of the primary root was affected by RAY1 mutation. In addition, the primary root of ray1 mutants grew with a slower rate compared to wild-type Arabidopsis. Taken together, these studies provide evidence that proper glycosylation of AGPs is important to AGP function in plant growth and development.
=== Professional ski wax technicians === Compared to the general public exposed to contaminated drinking water, professional ski wax technicians are more strongly exposed to PFAS (PFOA, PFNA, PFDA, PFHpA, PFDoDA) from the glide wax used to coat the bottom of skis to reduce the friction between the skis and snow. During the coating process, the wax is heated, which releases fumes and airborne particles. Compared to all other reported occupational and residential exposures, ski waxing had the highest total PFAS air concentrations.
Sources: en.wikipedia.org
Argiopine: contains 2,4-dihydroxyphenylacetic acid. It is also named Arg-636. Argiopinines: (4-hydroxyindol-3-yl) acetic acid is carried as the chromophore. These molecules are: Arg-630, Arg-658, Arg-659, Arg-744, Arg-759. Pseudoargiopinines: They contain a (indol-3-yl) acetic acid. This group is composed of: Arg-373, Arg-728, Arg-743.
=== Critiques and Limitations of the Agreement === The Algiers Peace Accords have been subject to substantial criticism from various stakeholders, including the Malian government, CMA, and international observers. One major critique centres on the lack of inclusivity in the agreement. The accord primarily focused on the interests of armed groups involved in the conflict, neglecting the concerns of sedentary populations. This exclusion has led to ongoing resentment and contributed to the formation of new militia groups, which further destabilised northern Mali. Another significant critique is that the accord inadvertently rewarded rebellion. By offering political and military concessions to groups that had taken up arms against the state, the peace process was seen by many in Mali as a capitulation. This perception fuelled the belief that future uprisings could extract similar concessions from the government. Additionally, the agreement's failure to address key economic drivers of the conflict, such as drug and arms trafficking, has been a notable shortcoming. Some signatories to the accord have been accused of continuing to engage in illicit trade, which undermines the peace process and fosters further instability.
On the first day, they'd have 100 mg in their system; their body would clear 10 mg, leaving 90 mg. On the second day, the patient would have 190 mg in total; their body would clear 19 mg, leaving 171 mg. On the third day, they'd be up to 271 mg total; their body would clear 27 mg, leaving 244 mg. As one can see, it would take many days for the total amount of drug within the body to come close to 1 gram (1000 mg) and achieve its full therapeutic effect. For a drug such as this, a doctor might prescribe a loading dose of one gram to be taken on the first day. That immediately gets the drug's concentration in the body up to the therapeutically-useful level.
It is recommended for mothers to initiate breastfeeding within the first hour after birth. Uninterrupted skin-to-skin contact and breastfeeding can begin immediately after birth, and should continue for at least one hour after birth. This period of infant-mother interaction, known generally as kangaroo care, or the "golden hour" during the immediate postpartum period, assists in the mother–child bonding for both mother and baby, and is thought to encourage instinctual breastfeeding behavior in the infant. Newborns who are immediately placed on their mother's skin have a natural instinct to latch on to the breast and start nursing, typically within one hour of birth. Success with breastfeeding in this "golden hour" increases the likelihood of successful breastfeeding at discharge. Skin-to-skin mother-baby contact should still occur, even if the baby is born by Cesarean section. The baby is placed on the mother in the operating room or the recovery area. If the mother is unable to immediately hold the baby, a family member can provide skin-to-skin care until the mother is able.
As topiramate inhibits carbonic anhydrase, use with other inhibitors of carbonic anhydrase (e.g., acetazolamide) increases the risk of kidney stones. Enzyme inducers (e.g., carbamazepine) can increase the elimination of topiramate, possibly necessitating dose escalations of topiramate. Topiramate may increase the plasma levels of phenytoin. Topiramate itself is a weak inhibitor of CYP2C19 and induces CYP3A4; a decrease in plasma levels of estrogens and digoxin has been noted during topiramate therapy. This can reduce the effectiveness of oral contraceptives (i.e., birth control pills); use of alternative birth control methods is recommended. Neither intrauterine devices (IUDs) nor Depo-Provera are affected by topiramate. Alcohol may cause increased sedation or drowsiness and increase the risk of having a seizure. As topiramate may result in acidosis, other treatments that also do so may worsen this effect. Oligohidrosis and hyperthermia were reported in post-marketing reports about topiramate; antimuscarinic drugs (like trospium) can aggravate these disorders.
Sources: en.wikipedia.org
== See also == State Sponsors of Terrorism (U.S. list) Specially Designated Nationals and Blocked Persons List United States sanctions on Bangladesh Caesar Syria Civilian Protection Act Rogue state Economic sanctions against the United States Permanent normal trade relations Arms Export Control Act Criticism of United States foreign policy European Union sanctions United Kingdom sanctions United States foreign adversaries
The UPMC Rooney Sports Complex is a multipurpose, multisport training, sports science, and sports medical complex located along the shore of the Monongahela River in Pittsburgh and is unique in that it combines training facilities for the University of Pittsburgh football team and the Pittsburgh Steelers NFL team in one location with an academically based sports science and medicine program. The complex consists of four centers which include the Center for Sports Medicine, Sports Training Center, Indoor Training Center, and the Fitness and Conditioning Center.
== Side effects == Side effects experienced with this product will resemble those of other benzodiazepines. Drowsiness and asthenia are common side effects. There has been a report of reversible hepatitis caused by clotiazepam.
== Tissue culture == In many cases, creation of functional tissues and biological structures in vitro requires extensive culturing to promote survival, growth and inducement of functionality. In general, the basic requirements of cells must be maintained in culture, which include oxygen, pH, humidity, temperature, nutrients and osmotic pressure maintenance. Tissue engineered cultures also present additional problems in maintaining culture conditions. In standard cell culture, diffusion is often the sole means of nutrient and metabolite transport. However, as a culture becomes larger and more complex, such as the case with engineered organs and whole tissues, other mechanisms must be employed to maintain the culture, such as the creation of capillary networks within the tissue.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.